Gilead Sciences Change in AP increased by 29.5% to -$67.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 36.2%, from -$105.00M to -$67.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests the company is effectively using supplier credit to manage cash flow, while a decrease indicates faster payment of liabilities.
Represents the net change in obligations to suppliers for goods and services received but not yet paid for. It is a crit...
Standard working capital metric; compared against days payable outstanding (DPO) at peer firms.
ms_change_in_accounts_payable| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$20.00M | -$91.00M | -$13.00M | $66.00M | $264.00M | -$272.00M | -$3.00M | -$29.00M | -$43.00M | $72.00M | -$83.00M | $359.00M | -$105.00M | -$162.00M | -$95.00M | -$67.00M |
| QoQ Change | — | -355.0% | +85.7% | +607.7% | +300.0% | -203.0% | +98.9% | -866.7% | -48.3% | +267.4% | -215.3% | +532.5% | -129.2% | -54.3% | +41.4% | +29.5% |
| YoY Change | — | — | — | +430.0% | — | -198.9% | +76.9% | -143.9% | -116.3% | +126.5% | <-999% | >999% | -245.8% | -95.2% | — | +36.2% |